Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

BACKGROUND: We evaluated the efficacy of carboplatin, irinotecan and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Vredenburgh, James J., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Coan, April, Threatt, Stevie, Friedman, Allan H., Friedman, Henry S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158844/
https://ncbi.nlm.nih.gov/pubmed/21590689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26188
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky